Home >  News >  Industry >  Pharma News >  Roche, Novo Nordisk...

Roche, Novo Nordisk Education Foundation ink pact to enhance Type 1 Diabetes care for children in India

"Support will include free diabetes monitoring and management kits including insulin pens, needles, insulin cartridges, glucometers, strips, and lancets," the release stated.;

By - Ruchika Sharma
Published On 2022-08-05 06:18 GMT   |   Update On 2022-08-05 06:18 GMT
Advertisement

Bengaluru: Novo Nordisk Education Foundation (NNEF) and Roche Diabetes Care India (RDC) today signed a Memorandum of Understanding (MoU) to improve access to care for underprivileged children living with Type 1 diabetes (T1D) in India.

This partnership is part of a global collaboration between the two parties and will impact close to 4,000 children with Type 1 diabetes in India. It will also provide education and training for doctors and nurses, and enhance awareness about diabetes and its management among children with T1D and their families.

"Support will include free diabetes monitoring and management kits including insulin pens, needles, insulin cartridges, glucometers, strips, and lancets," the release stated.

The partnership will provide care to people living with diabetes across specified centres affiliated with NNEF in 12 states and 1 union territory including Karnataka, Maharashtra, Telangana, Tamil Nadu, Madhya Pradesh, Delhi, West Bengal, Bihar, Punjab, Uttar Pradesh, Kerala, Rajasthan, and Jammu & Kashmir.

Advertisement
This partnership is part of NNEF's Changing Diabetes in Children (CDiC) programme - a public-private partnership that provides free life-saving medicine and supplies for children and young people living with Type 1 diabetes in low- and middle-income countries up to 25 years of age.
India is home to the second largest number (74.2 million) of adults with diabetes worldwide. More significantly, nearly 53.1% of India's diabetes population remains undiagnosed. Further, at an estimated 229,400, the country also ranks among top 10 nations with the highest number of children and adolescents having Type 1 diabetes (0–19 years). This data brings to fore the urgent need for awareness, early diagnosis and therapy adherence through a sustainable healthcare mechanism.
Mr. Vikrant Shrotriya, Managing Trustee, Novo Nordisk Education Foundation, said "At NNEF, we believe that everyone deserves access to timely diabetes care, especially vulnerable patients who may lack access. Our collaboration with Roche Diabetes Care India is a step in this direction and will provide access to diabetes management and care for close to 4,000 underprivileged children who live with Type 1 diabetes. This partnership comes on the back of a long and successful collaboration between CDiC and Roche globally to create healthier lives for those living with diabetes. I am grateful to all our partners who have collaborated with us on this journey. Working together is the best way to tackle healthcare access challenges at scale and create real ground level impact. Clearly, we are not alone in this fight to defeat diabetes."
Talking at the event, Mr. Omar Sherief Mohammad, Cluster Head – India, Middle East, and Africa, Roche Diabetes Care, said "Roche Diabetes Care is committed to enhancing access to diabetes care so that we can bring true relief to people with diabetes everywhere. We believe in the power of collective impact and that united we can create sustainable impact that goes beyond just providing medical support. It involves creating an eco-system that enables early diagnosis and treatment, and provides the required socio- economic support critical to therapy adherence. We are very proud to partner with NNEF, who has been dedicated towards this cause. Our initiatives in India with CDiC are part of our shared global efforts in creating such an ecosystem of care to provide better access to diabetes management to children with Type 1 diabetes."
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

NPPA Warns Drugmakers Against Arbitrary Pricing, Calls for MRP Uniformity

NPPA Committee Asks Intas to Clarify Patent Discrepancy in Clozapine ER Pricing Plea

India Cuts API Imports, Disburses Rs 1,008 Cr Under PLI Schemes, Parliament Told

PCI President Montu Patel granted pre-arrest bail in corruption case

Alembic Pharma gets USFDA nod for anticonvulsant drug Carbamazepine Extended Release

Licences of 2 pharma stores suspended for unethical trade practices

16912 Jan Aushadhi Kendras opened till June 30: Minister

Mankind Pharma incorporates wholly owned subsidiary in Sri Lanka